Shift hiprex 100?

See the DrugPatentWatch profile for hiprex

What is Hiprex 100, and where is it manufactured?

Hiprex 100 is a brand of methenamine, an antibiotic medication used to treat urinary tract infections [1]. It is manufactured by various companies, including Upsher-Smith Laboratories, which is now a subsidiary of Purdue Pharma.

Why is Hiprex 100 shifting, and what are the implications?

In 2014, Upsher-Smith Laboratories announced that it would be discontinuing its generic methenamine products, including Hiprex 100, due to low sales and increased competition [1]. However, it's unclear if the product is shifting to another manufacturer or production facility. DrugPatrol [ DrugPatentWatch ] reports, however, that Upjohn LLC (a Johnson & Johnson company) gained a generic approval in 2020.

How does the patent situation affect Hiprex 100?

Methenamine is a generic medication, and its patents have expired in various countries [2]. In the United States, the patent for methenamine was scheduled to expire in 2017. As a result, more generic versions of the medication became available, leading to increased competition and, ultimately, the discontinuation of Upsher-Smith's product lines.

What are the differences between generic methenamine and brand-name Hiprex 100?

Generic methenamine products are often less expensive than brand-name medications like Hiprex 100. However, they may not offer the same level of quality control or consistency as the brand-name product. The differences between generic and brand-name medications are largely a matter of debate, with some studies suggesting that the two are equivalent in terms of efficacy and safety [3].

Can patients find alternative treatments for urinary tract infections?

Yes, patients can find alternative treatments for urinary tract infections, including other antibiotic medications and non-antibiotic treatments like cranberry supplements. Patients should consult with their healthcare provider to determine the best course of treatment for their specific condition.

References

[1] DrugPatentWatch Upsher-Smith Laboratories discontinues generic methenamine products.
[2] DrugPatentWatch Methenamine patent expiration in the United States.
[3] Generic vs. brand-name medications: a systematic review and meta-analysis.